Therapeutic Protein Designer

SkillMedia

Lets your agent design new therapeutic proteins, from backbone generation to sequence design and structure validation.

Then ask your AI: use the Therapeutic Protein Designer skill

Details

Instructions available. Your AI can read the instructions. Execution depends on the setup they require.

Add it as a step in a pipeline you build on Ahel, or connect Ahel to Claude, ChatGPT, Cursor, Claude Code or Codex and ask your AI to use it.

About this skill

AI-guided de novo protein design, RFdiffusion backbone generation, ProteinMPNN sequence design, structure validation (pLDDT, pTM, MPNN scores). Use for designing therapeutic protein binders, novel scaffolds, enzyme variants, and miniprotein/protein-interface design before experimental validation.

What this skill tells your AI

The instructions your AI receives, as published by mims-harvard/tooluniverse in skills/tooluniverse-protein-therapeutic-design/SKILL.md and read by Ahel’s review.

AI-guided de novo protein design using RFdiffusion backbone generation, ProteinMPNN sequence optimization, and structure validation for therapeutic protein development.

KEY PRINCIPLES:

  1. Structure-first - Generate backbone geometry before sequence
  2. Target-guided - Design binders with target structure in mind
  3. Iterative validation - Predict structure to validate designs
  4. Developability-aware - Consider aggregation, immunogenicity, expression
  5. Evidence-separated - Report folding, pose, geometry, protonation and experimental evidence independently
  6. Actionable output - Provide sequences ready for experimental testing
  7. English-first queries - Always use English terms in tool calls

Therapeutic protein design starts with the target interaction. What binding surface do you need to cover? A small pocket = nanobody or peptide. A large flat surface = designed protein. Stability, immunogenicity, and manufacturability constrain the design space.

LOOK UP, DON'T GUESS

When uncertain about any scientific fact, SEARCH databases first rather than reasoning from memory. A database-verified answer is always more reliable than a guess.


COMPUTE, DON'T DESCRIBE

When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it.

When to Use

Apply when user asks to:

  • Design a protein binder, therapeutic protein, or scaffold
  • Optimize a protein sequence for function
  • Design a de novo enzyme
  • Generate protein variants for target binding

Workflow Overview

Phase 1: Target Characterization
  Get structure (PDB, EMDB cryo-EM, AlphaFold), identify binding epitope

Phase 2: Backbone Generation (RFdiffusion)
  Define constraints, generate >= 5 backbones, filter by geometry

Phase 3: Sequence Design (ProteinMPNN)
  Design >= 8 sequences per backbone, sample with temperature control

Phase 4: Structure Validation (ESMFold/AlphaFold2)
  Predict structure, compare to backbone, assess pLDDT/pTM

Phase 5: Developability Assessment
  Aggregation, pI, expression prediction

Phase 6: Report Synthesis
  Ranked candidates, FASTA, experimental recommendations

Critical Requirements

For iterative campaigns, conflicting predictions, glycosylated receptor checks, conditional pH binding, or competition preparation, use Protein Design Campaign alongside this workflow. Verify installed tool schemas before executing examples; model confidence and successful execution do not establish binding.

Report-First Approach (MANDATORY)

  1. Create [TARGET]_protein_design_report.md first with section headers
  2. Progressively update as designs are generated
  3. Output [TARGET]_designed_sequences.fasta and [TARGET]_top_candidates.csv

Design Documentation (MANDATORY)

Every design MUST include: Sequence, Length, Target, Method, and available Quality Metrics (pLDDT, pTM, MPNN score, binding prediction). Mark unavailable metrics unmeasured or uncomputed; do not fabricate binding predictions or experimental values.


NVIDIA NIM Tools

ToolPurposeKey Parameter
NvidiaNIM_rfdiffusion (requires NVIDIA_API_KEY env var; free key at build.nvidia.com)Backbone generationcontigs + input_pdb (both required), diffusion_steps (NOT num_steps; default 15)
NvidiaNIM_proteinmpnn (requires NVIDIA_API_KEY env var; free key at build.nvidia.com)Sequence designinput_pdb (required; NOT pdb or pdb_string), num_seq_per_target, sampling_temp (a list)
ESMFold_predict_structureFast validationsequence (NOT seq)
NvidiaNIM_alphafold2 (requires NVIDIA_API_KEY env var; free key at build.nvidia.com)High-accuracy structure inference from sequencesequence, algorithm
NvidiaNIM_esm2_650m (requires NVIDIA_API_KEY env var; free key at build.nvidia.com)Sequence embeddingssequences, format

Common Parameter Mistakes

ToolWrongCorrect
NvidiaNIM_rfdiffusion (requires NVIDIA_API_KEY)num_steps=50diffusion_steps=50 (plus required contigs and input_pdb)
NvidiaNIM_proteinmpnn (requires NVIDIA_API_KEY)pdb=content or pdb_string=contentinput_pdb=content
ESMFold_predict_structureseq="MVLS..."sequence="MVLS..."
NvidiaNIM_alphafold2 (requires NVIDIA_API_KEY)seq="MVLS..."sequence="MVLS..."

NVIDIA NIM Requirements

  • API Key: NVIDIA_API_KEY environment variable required
  • Rate limits: 40 RPM (1.5 second minimum between calls)
  • AlphaFold2 may return 202 (polling required); RFdiffusion and ESMFold are synchronous

Supporting Tools

ToolPurposeKey Parameters
PDBe_get_uniprot_mappingsFind PDB structuresuniprot_id
RCSBData_get_entryDownload PDB filepdb_id
alphafold_get_predictionGet AlphaFold DB structureaccession
EMDB_search_structuresSearch cryo-EM mapsquery
EMDB_get_structureGet entry detailsentry_id
UniProt_get_entry_by_accessionGet target sequenceaccession
InterPro_get_protein_domainsGet domainsaccession

Folding and Developability Screening

These are illustrative computational screening tiers, not binding-evidence grades or calibrated success probabilities. Benchmark screening with appropriate controls. Monomer pLDDT/pTM cannot establish a complex pose, affinity, cross-species binding or pH selectivity. Report those dimensions separately, including missing evidence.

TierCriteria
T1 (strongest in this screen)pLDDT >85, pTM >0.8, low aggregation, neutral pI
T2pLDDT >75, pTM >0.7, acceptable developability
T3pLDDT >70, pTM >0.65, developability concerns
T4Failed validation or major developability issues

Completeness Checklist

  • Target structure obtained (PDB or predicted)
  • Binding epitope identified
  • >= 5 backbones generated, top 3-5 selected
  • >= 8 sequences per backbone, MPNN scores reported
  • All sequences validated (ESMFold), pLDDT/pTM reported, >= 3 passing
  • Developability assessed (aggregation, pI, expression)
  • Ranked candidate list, FASTA file, experimental recommendations

Reference Files

  • DESIGN_PROCEDURES.md - Phase-by-phase code examples, sampling parameters, fallback chains
  • TOOLS_REFERENCE.md - Complete tool documentation with code examples
  • EXAMPLES.md - Sample design workflows and outputs
  • CHECKLIST.md - Detailed phase checklists and quality metrics
  • design_templates.md - Report templates and output format examples

Signals

GitHub stars
2k
Forks
261
Last commit
Oct 2026
Advanced
Item type
skill
Key
tooluniverse-protein-therapeutic-design-mims-harvard
Source
github.com/mims-harvard/tooluniverse